Table 6.
Clinicopathological characteristics correlated with categorical low and high p-RKIP expression both in the nucleus and cytoplasm
| Clinico-pathological characteristics | Patients (n=133) | pRKIP expression | p value | |
|---|---|---|---|---|
|
| ||||
| pRKIP low in nucleus and cytoplasm (n=74) | pRKIP high in nucleusand cytoplasm (n=59) | |||
| Age (≤50/>50 years) | 34/99 | 19/55 | 15/44 | 0.974 |
| Size (≤20/21-50/>50 mm) | 78/49/6 | 47/25/2 | 31/24/4 | 0.140 |
| Grade (I/II/III) | 27/58/47 m1 | 11/33/30 | 16/25/17 m1 | 0.154 |
| Nodal status (negative/positive) | 68/63 m2 | 36/37 m1 | 32/26 m1 | 0.505 |
| Oestrogen receptor status (ER-/ER+) | 39/92 m2 | 24/50 | 15/42 m2 | 0.450 |
| Progesterone receptor status (PR-/PR+) | 71/60 m2 | 41/33 | 30/27 m2 | 0.753 |
| HER2 (HER2-/HER2+) | 115/17 m1 | 61/13 | 54/4 m1 | 0.070 |
| Ki67 (≤15/>15) | 96/33 m4 | 51/21 m2 | 45/12 m2 | 0.296 |
| TUNEL (≤0.33/>0.33) | 73/52 m8 | 42/28 m4 | 31/24 m4 | 0.683 |
| Necrosis (absent/present) | 69/62 m2 | 37/37 | 32/25 m2 | 0.485 |
| Chemotherapy (no/yes) | 78/55 | 41/33 | 37/22 | 0.395 |
| Radiotherapy (no/yes) | 74/59 | 42/32 | 32/27 | 0.771 |
| Endocrine therapy (no/yes) | 29/103 m1 | 16/57 m1 | 13/46 | 0.987 |
| DFS (months) | n=68 m6 | n=56 m3 | 0.009 | |
| Mean (95% CI) | 77.6 (70.1-85.1) | 95.4 (89.0-101.8) | ||
m (number of patients)=missing.